Clincosm LogoSign in Get a demo

immune checkpoint inhibitors

Showing 1 - 20 of 20
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colonic Tumors, Neoadjuvant Therapy, Immune Checkpoint Inhibitors Trial in Nanning (Tislelizumab, Oxaliplatin, Capecitabine)

Recruiting
  • Colonic Neoplasms
  • +2 more
  • Nanning, Guangxi, China
    The First Affiliated Hospital of Guangxi Medical University
Nov 9, 2023

Tumors, Kidney Tumors, Urologic Tumors Trial in Nanjing (Toripalimab, Axitinib, Lenvatinib)

Recruiting
  • Neoplasms
  • +12 more
  • Nanjing, Jiangsu, China
    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
Oct 28, 2023

Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus, Immune Checkpoint Inhibitors Trial in Nanning (Cadonilimab,

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • +2 more
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Sep 13, 2023

Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors Trial (Cadonilimab, Gemcitabine, Cisplatin)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Immune Checkpoint Inhibitors
  • (no location specified)
Jun 1, 2023

Genomic Data of American Indian Patient Population

Active, not recruiting
  • Immune Checkpoint Inhibitors
  • +6 more
  • Immunotherapy
  • Tucson, Arizona
  • +5 more
May 8, 2023

Immunotherapy, Immune Checkpoint Inhibitors, Immune-related Adverse Event Trial in Amiens (blood retriewal)

Recruiting
  • Immunotherapy
  • +5 more
  • blood retriewal
  • Amiens, Picardie, France
    CHU Amiens Picardie
Apr 3, 2023

Gemcitabine, Biliary Tract Cancer, Immune Checkpoint Inhibitors Trial in Hangzhou (Gemcitabine-based chemo regimen combined with

Not yet recruiting
  • Gemcitabine
  • +2 more
  • Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors
  • Hangzhou, Zhejiang, China
    Hangzhou First People's Hospital
Aug 2, 2022

Lung Cancer, Chronic Stress Disorder, Immune Checkpoint Inhibitors Trial in Changsha (Gut microbiota detection, Peripheral

Recruiting
  • Lung Cancer
  • +2 more
  • Gut microbiota detection
  • Peripheral immune cells signature detaction
  • Changsha, Hunan, China
    Department of Oncology, The Second Xiangya Hospital, Central Sou
Jul 26, 2022

Cancer, Fecal Microbiota Transplantation, Immune Checkpoint Inhibitors Trial in Zurich (Fecal Microbiota Transplantation (FMT))

Recruiting
  • Cancer
  • +2 more
  • Fecal Microbiota Transplantation (FMT)
  • Zurich, Switzerland
    University of Zurich, University Hospital Zurich
Jun 14, 2022

NSCLC, Immune Checkpoint Inhibitors Trial in Seoul (F-18 FDG PET/CT)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Immune Checkpoint Inhibitors
  • F-18 FDG PET/CT
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jun 15, 2022

Myocarditis, Immune Checkpoint Inhibitors, Cardiotoxicity Trial in Adelaide (Immune Checkpoint Inhibitors)

Recruiting
  • Myocarditis
  • +3 more
  • Immune Checkpoint Inhibitors
  • Adelaide, South Australia, Australia
    Flinders Medical Centre
Apr 21, 2022

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • +9 more
  • Radiotherapy for targeted lesions and PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus

Recruiting
  • Recurrent Cervical Carcinoma
  • +9 more
  • Tislelizumab plus radiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

irAE Prediction of Anti-PD-1/L1 in Lung Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • Lung Cancer
    • Beijing, China
      Peking Union Medical College Hospital
    Mar 31, 2022

    Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,

    Recruiting
    • Recurrent Cervical Carcinoma
    • +5 more
    • Anti-PD-1 antibody camrelizumab
    • Albumin-bound paclitaxel
    • Beijing, Beijing, China
      Lei Li
    Mar 12, 2022

    Metabolism Disorder, Cancer, Immune Checkpoint Inhibitors Trial in Paris (calorimetry, impedance measurement at baseline and

    Recruiting
    • Metabolism Disorder
    • +2 more
    • calorimetry, impedance measurement at baseline and after 3 months of treatment
    • Paris, Île-de-France, France
    • +1 more
    Nov 15, 2021

    Plaque, Atherosclerotic, Immune Checkpoint Inhibitors, Programmed Cell Death Protein 1 Inhibitor Trial in Hangzhou (PD-1 immune

    Recruiting
    • Plaque, Atherosclerotic
    • +4 more
    • PD-1 immune checkpoint blockades
    • Hangzhou, Zhejiang, China
      The Second Affiliated Hospital of Zhejiang University, School of
    Nov 16, 2021

    Stage IV Melanoma, Advanced Lung Cancer, Stage IV NSCLC Trial in Boston (Educational Video and QPL List, Usual Care)

    Recruiting
    • Stage IV Melanoma
    • +7 more
    • Educational Video and QPL List
    • Usual Care
    • Boston, Massachusetts
      Massachusetts General Hospital
    Jul 26, 2021

    Therapeutic Patient Education, Immune Checkpoint Inhibitors, Melanoma Trial in France (Therapeutic education program, Usual

    Recruiting
    • Therapeutic Patient Education
    • +6 more
    • Therapeutic education program
    • Usual Information
    • Angers, France
    • +11 more
    May 17, 2021

    Hepatocellular Carcinoma, Immune Checkpoint Inhibitors Trial in Changsha (Camrelizumab combined Apatinib regimen)

    Recruiting
    • Hepatocellular Carcinoma
    • Immune Checkpoint Inhibitors
    • Camrelizumab combined Apatinib regimen
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 29, 2021